Surfen, a proteoglycan binding agent, reduces inflammation but inhibits remyelination in murine models of Multiple Sclerosis

Proteoglycans are promising therapeutic targets in Multiple Sclerosis (MS), because they regulate many aspects of the immune response. This was studied using surfen, an agent that binds both heparan sulphate proteoglycans (HSPGs) and chondroitin sulphate proteoglycans (CSPGs). Initial cell culture w...

Descripción completa

Detalles Bibliográficos
Autores principales: Warford, Jordan R., Lamport, Anna-Claire, Clements, Derek R., Malone, Alicia, Kennedy, Barry E., Kim, Youra, Gujar, Shashi A., Hoskin, David W., Easton, Alexander S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5755315/
https://www.ncbi.nlm.nih.gov/pubmed/29301568
http://dx.doi.org/10.1186/s40478-017-0506-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5755315/
https://www.ncbi.nlm.nih.gov/pubmed/29301568
http://dx.doi.org/10.1186/s40478-017-0506-9

Ejemplares similares